Irinotecan: Difference between revisions

Jump to navigation Jump to search
No edit summary
(No difference)

Revision as of 20:36, 20 May 2009

Irinotecan
Error creating thumbnail: File missing
Clinical data
Pregnancy
category
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • POM (UK), ℞-only (U.S.)
Pharmacokinetic data
BioavailabilityNA
MetabolismHepatic glucuronidation
Elimination half-life6 to 12 hours
ExcretionBiliary and renal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC33H38N4O6
Molar mass586.678 g/mol
677.185 g/mol (hydrochloride)

WikiDoc Resources for Irinotecan

Articles

Most recent articles on Irinotecan

Most cited articles on Irinotecan

Review articles on Irinotecan

Articles on Irinotecan in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Irinotecan

Images of Irinotecan

Photos of Irinotecan

Podcasts & MP3s on Irinotecan

Videos on Irinotecan

Evidence Based Medicine

Cochrane Collaboration on Irinotecan

Bandolier on Irinotecan

TRIP on Irinotecan

Clinical Trials

Ongoing Trials on Irinotecan at Clinical Trials.gov

Trial results on Irinotecan

Clinical Trials on Irinotecan at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Irinotecan

NICE Guidance on Irinotecan

NHS PRODIGY Guidance

FDA on Irinotecan

CDC on Irinotecan

Books

Books on Irinotecan

News

Irinotecan in the news

Be alerted to news on Irinotecan

News trends on Irinotecan

Commentary

Blogs on Irinotecan

Definitions

Definitions of Irinotecan

Patient Resources / Community

Patient resources on Irinotecan

Discussion groups on Irinotecan

Patient Handouts on Irinotecan

Directions to Hospitals Treating Irinotecan

Risk calculators and risk factors for Irinotecan

Healthcare Provider Resources

Symptoms of Irinotecan

Causes & Risk Factors for Irinotecan

Diagnostic studies for Irinotecan

Treatment of Irinotecan

Continuing Medical Education (CME)

CME Programs on Irinotecan

International

Irinotecan en Espanol

Irinotecan en Francais

Business

Irinotecan in the Marketplace

Patents on Irinotecan

Experimental / Informatics

List of terms related to Irinotecan

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Irinotecan is a chemotherapy agent that is a topoisomerase 1 inhibitor. Chemically, it is a semisynthetic analogue of the natural alkaloid camptothecin.

Its main use is in colon cancer, particularly in combination with other chemotherapy agents. This includes the regimen FOLFIRI which consists of infusional 5-fluorouracil, leucovorin, and irinotecan.

Irinotecan was first introduced in Japan by the Pharmaceutical arm of Yakult Honsha as Campto®. In 1994, it received accelerated FDA approval in the United States, where it is now marketed by Pfizer as Camptosar®. It is also known as CPT-11.

Mechanism

Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.

Side effects

The most significant adverse effects of irinotecan are severe diarrhea and extreme suppression of the immune systems.

Diarrhea

Irinotecan-associated diarrhea is severe and clinically significant, sometimes leading severe dehydration requiring hospitalization or intensive care unit admission. This side effect is managed with the aggressive use of antidiarrheals such as loperamide or Lomotil with the first loose bowel movement.

Immunosuppression

The immune system is adversely impacted by irinotecan. This is reflected in dramatically lowered white blood cell counts in the blood, in particular the neutrophils. While the bone marrow, where neutrophils are made, cranks up production to compensate, the patient may experience a period of neutropenia, that is, a clinical lack of neutrophils in the blood.

Pharmacogenomics

Irinotecan is converted by an enzyme into its active metabolite SN-38, which is in turn inactivated by the enzyme UGT1A1. People with variants of the UGT1A1 called TA7, also known as the *28 variant, express fewer UGT1A1 enzymes in their liver. During chemotherapy, these patients effectively receive a larger than expected dose because their bodies are not able to clear irinotecan as fast as others. In studies this corresponds to higher incidences of severe diarrhea and neutropenia [1].

In 2004, a clinical study was performed that both validated prospectively the association of the *28 variant with greater toxicity and the ability of genetic testing in predicting that toxicity before chemotherapy administration [2].

In 2005, the FDA made changes to the labelling of irinotecan to add pharmacogenomics recommendations that patients with polymorphisms in UGT1A1 gene, specifically the *28 variant, should perhaps receive reduced drug doses. Irinotecan is one of the first widely-used chemotherapy agents that is dosed for each patient according to his genotype[3].

See also

References

  1. Journal of Clinical Oncology, Vol 22, No 8 April 15, 2004: pp. 1382-1388
  2. Innocenti F; et al. (2004). "Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan". Journal of Clinical Oncology. 22 (8): 1382–88. PMID 15007088. Unknown parameter |month= ignored (help)
  3. O'Dwyer PJ, Catalano RP (2006). "Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy". Journal of Clinical Oncology. 24 (28): 4534–38. PMID 17008691. Unknown parameter |month= ignored (help)

External links

Template:SIB de:Irinotecan fi:Irinotekaani

Template:WH Template:WikiDoc Sources